@article{1ce3a501aa694db7a076d54a9987ba1f,
title = "Emerging Therapies for Inflammatory Bowel Disease",
abstract = "Inflammatory bowel disease (IBD) is a chronic heterogeneous group of diseases that has undergone major advances in the understanding of its etiology and pathogenesis in recent years. The development of biologics had resulted in better overall management of the disease, including lower rates of surgery and better long-term clinical and patient-reported outcomes. Treatment modalities have either been newly developed or extrapolated from their approved use for a different indication. Modes of action and treatment targets have varied as well. Treatments such as vedolizumab and ustekinumab, as well as second-generation corticosteroids have been approved by the US Food and Drug Administration (FDA) for the treatment of IBD. Other agents are currently being developed at various stages of clinical trials including anti-adhesion agents such as etrolizumab and abrilumab, JAK inhibitors such as tofacitinib, and anti-trafficking molecules. Toll-like receptors and phosphatidylcholine are also new promising emerging targets that are being investigated in phase 3 clinical trials. It is projected that many therapies will become available in the coming years if supported by the results of current clinical trials. This will provide IBD patients with a wide array of options and allow physicians to choose the best therapies for each individual patient.",
keywords = "Crohn{\textquoteright}s disease, Inflammatory bowel disease, Therapy, Ulcerative colitis",
author = "Roni Weisshof and {El Jurdi}, Katia and Nada Zmeter and Rubin, {David T.}",
note = "Funding Information: Disclosures. Roni Weisshof received consultant fees from Janssen. Katia El Jurdi and Nada Zmeter have no relevant disclosures. David T. Rubin is a consultant and has received grant support from Abbvie, Genentech/Roche, Jans-sen, Takeda, Pfizer, Amgen, Samsung/Bioepis. Funding Information: No funding or sponsorship was received for this study or publication of this article. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published. Roni Weisshof received consultant fees from Janssen. Katia El Jurdi and Nada Zmeter have no relevant disclosures. David T. Rubin is a consultant and has received grant support from Abbvie, Genentech/Roche, Janssen, Takeda, Pfizer, Amgen, Samsung/Bioepis. This article is based on previously conducted studies and does not directly contain any studies with human participants or animals performed by any of the authors. Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. To view enhanced digital features for this article go to 10.6084/m9.figshare.7083086. Publisher Copyright: {\textcopyright} 2018, The Author(s).",
year = "2018",
month = nov,
day = "1",
doi = "10.1007/s12325-018-0795-9",
language = "English",
volume = "35",
pages = "1746--1762",
journal = "Advances in Therapy",
issn = "0741-238X",
number = "11",
}